Ruxolitinib

Ruben A. Mesa; Uma Yasothan; Peter Kirkpatrick

doi:10.1038/nrd3652

Ruxolitinib

Ruben A. Mesa, Uma Yasothan, Peter Kirkpatrick

Hematology/Oncology

Research output: Contribution to journal › Review article › peer-review

120 Scopus citations

Abstract

In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.

Original language	English (US)
Pages (from-to)	103-104
Number of pages	2
Journal	Nature Reviews Drug Discovery
Volume	11
Issue number	2
DOIs	https://doi.org/10.1038/nrd3652
State	Published - Feb 1 2012

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Access to Document

10.1038/nrd3652

Cite this

@article{402e14dac7b1416c91e04d7ae8264e28,

title = "Ruxolitinib",

abstract = "In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.",

author = "Mesa, {Ruben A.} and Uma Yasothan and Peter Kirkpatrick",

year = "2012",

month = feb,

day = "1",

doi = "10.1038/nrd3652",

language = "English (US)",

volume = "11",

pages = "103--104",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Ruxolitinib

AU - Mesa, Ruben A.

AU - Yasothan, Uma

AU - Kirkpatrick, Peter

PY - 2012/2/1

Y1 - 2012/2/1

N2 - In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.

AB - In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.

UR - http://www.scopus.com/inward/record.url?scp=84856509517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856509517&partnerID=8YFLogxK

U2 - 10.1038/nrd3652

DO - 10.1038/nrd3652

M3 - Review article

C2 - 22293561

AN - SCOPUS:84856509517

SN - 1474-1776

VL - 11

SP - 103

EP - 104

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

IS - 2

ER -

Ruxolitinib

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this